Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides-Reference-Cited by-同舟云学术

Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides

Published:2024-08-28 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Fu Quanlan¹,Luo Yuandong¹,Li Junjie²,Zhang Pingping³,Tang Shuxian³,Song Xinyi⁴,Fu Jiawei⁴,Liu Mengqi¹,Mo Rongmi⁴,Wei Ming⁵,Li Hejie⁶,Liu Xiaosong²³⁴,Wang Tianfang⁶,Ni Guoying²³⁴

Affiliation:

1. Medical School of Guizhou University, Guiyang, Guizhou, China

2. R&D Department, Zhongao Bio-pharmaceutical Technology Co., Ltd., Zhongshan, Guangdong Province, China

3. Cancer Research Institute, The First People’s Hospital of Foshan, Foshan, Guangdong, China

4. The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China

5. School of Medical Sciences, Griffith University, Gold Coast, QLD, Australia

6. Centre for Bioinnovation, University of the Sunshine Coast, Maroochydore BC, QLD, Australia

Funder

Deng Feng project of Foshan First People’s Hospital

National Science Foundation of Guangdong province

National Natural Science Foundation of China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2385654

Reference103 articles.

1. Mapping Cancer Origins

2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

3. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian SL;N Engl J Med,2012

4. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

5. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic;Chan TA;Ann Oncol,2019